```markdown
---
application_number: 761279Orig1s000
letter_type: Complete Response
company_name: Eli Lilly and Company
contact_name: Conrad J. Wong, Ph.D.
contact_title: Senior Director, Global Regulatory Affairs – North America
address:
  street: Lilly Corporate Center, Drop Code 2543
  city: Indianapolis
  state: IN
  zip: 46285
contact_phone: (240) 402-4276
contact_email: kelly.richards@fda.hhs.gov
submission_date: 2022-03-30
response_date: 2023-03-30
product_name: LY3074828 injection
indication: Moderately to Severely Active Ulcerative Colitis
facility:
  name: ELI LILLY AND COMPANY
  location: Indianapolis, Indiana
  fei: 1819470
director_name: Julie Beitz, MD
office: Office of Immunology and Inflammation
division: Office of New Drugs
signed_by: JULIE G BEITZ
signature_date: 2023-03-30
---

## Critical Data

- **Application Number:** 761279Orig1s000  
- **Submission Type:** Biologics License Application (BLA)  
- **Letter Type:** Complete Response  
- **Sponsor:** Eli Lilly and Company  
- **Contact Person:** Conrad J. Wong, Ph.D. – Senior Director, Global Regulatory Affairs – North America  
- **Product Name:** LY3074828 injection  
- **Indication:** Moderately to Severely Active Ulcerative Colitis  
- **Original Submission Date:** March 30, 2022  
- **FDA Response Date:** March 30, 2023  
- **Facility Name:** ELI LILLY AND COMPANY  
- **Facility Location:** Indianapolis, Indiana  
- **FDA Establishment Identifier (FEI):** 1819470  
- **Director, Reviewing Division:** Julie Beitz, MD  
- **Regulatory Contact at FDA:**  
  - Name: Kelly Richards  
  - Phone: (240) 402-4276  
  - Email: kelly.richards@fda.hhs.gov  

---

# CENTER FOR DRUG EVALUATION AND RESEARCH

## APPLICATION NUMBER: 761279Orig1s000  
### OTHER ACTION LETTERS  

---

**BLA 761279**  
**COMPLETE RESPONSE**  
**Eli Lilly and Company**  
Attention: Conrad J. Wong, Ph.D.  
Senior Director  
Global Regulatory Affairs – North America  
Lilly Corporate Center, Drop Code 2543  
Indianapolis, IN 46285  

Dear Dr. Wong:

Please refer to your biologics license application (BLA) dated and received March 30, 2022, submitted under section 351(a) of the Public Health Service Act for LY3074828 injection for moderately to severely active ulcerative colitis.

We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues.

---

## FACILITY INSPECTIONS

Following pre-license inspection of the ELI LILLY AND COMPANY, Indianapolis, Indiana (FEI 1819470), manufacturing facility listed in this application, FDA conveyed deficiencies to the representative of the facility. Satisfactory resolution of these deficiencies is required before this application may be approved.

---

## PRESCRIBING INFORMATION

Submit draft labeling that is responsive to your electronic communication dated March 15, 2023, for the Prescribing Information and Medication Guide and March 2, 2023, for the Instructions for Use.

Prior to resubmitting the labeling:

- Use the SRPI checklist to correct any formatting errors to ensure conformance with the format items in regulations and guidances.
- Submit updated content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format as described at [FDA.gov](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm).

Please resubmit the proposed proprietary name when you respond to the application deficiencies.

---

## SAFETY UPDATE

When you respond to the above deficiencies, include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b). The safety update should include data from all nonclinical and clinical studies/trials of the product under consideration regardless of indication, dosage form, or dose level.

1. Describe in detail any significant changes or findings in the safety profile.
2. When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows:
   - Present new safety data from the studies/clinical trials for the proposed indication using the same format as in the original submission.
   - Present tabulations of the new safety data combined with the original application data.
   - Include tables that compare frequencies of adverse events in the original application with the retabulated frequencies described above.
   - For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in clinical trials.
3. Present a retabulation of the reasons for premature trial discontinuation by incorporating the drop-outs from the newly completed trials. Describe any new trends or patterns identified.
4. Provide case report forms and narrative summaries for each subject who:
   - Died during a clinical trial, or
   - Did not complete a trial because of an adverse event.
   - In addition, provide narrative summaries for serious adverse events.
5. Describe any information that suggests a substantial change in the incidence of common, but less serious, adverse events between the new data and the original application data.
6. Provide updated exposure information for the clinical studies/trials (e.g., number of subjects, person time).
7. Provide a summary of worldwide experience on the safety of this product. Include an updated estimate of use for product marketed in other countries.
8. Provide English translations of current approved foreign labeling not previously submitted.

---

## ADDITIONAL COMMENTS

We have the following comments/recommendations that are not approvability issues:

### MICROBIOLOGY

[Redacted]

---

If you have any questions, contact Kelly Richards, Senior Regulatory Health Project Manager, at (240) 402-4276 or email at kelly.richards@fda.hhs.gov

Sincerely,  
{See appended electronic signature page}  

Julie Beitz, MD  
Director  
Office of Immunology and Inflammation  
Office of New Drugs  
Center for Drug Evaluation and Research  

---

### Signature

/s/  
**JULIE G BEITZ**  
03/30/2023 10:57:26 AM  
Signature Page 1 of 1
```